Monopar Therapeutics Inc

詳細情報 Monopar Therapeutics Inc 企業名

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.

企業情報

企業コードMNPR

会社名Monopar Therapeutics Inc

上場日Dec 19, 2019

最高経営責任者「CEO」Dr. Chandler D. Robinson, M.D.

従業員数16

証券種類Ordinary Share

決算期末Dec 19

本社所在地1000 Skokie Blvd Ste 350

都市WILMETTE

証券取引所NASDAQ Capital Market Consolidated

国United States of America

郵便番号60091-1146

電話番号18473880349

ウェブサイトhttps://www.monopartx.com/

企業コードMNPR

上場日Dec 19, 2019

最高経営責任者「CEO」Dr. Chandler D. Robinson, M.D.

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

73.47K

--

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

--

Ms. Lavina Talukdar

Independent Director

14.00K

--

Ms. Kim R. Tsuchimoto

Director

11.49K

--

Mr. Arthur J. Klausner

Independent Director

6.17K

--

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

--

Mr. Vu Quan

Chief Financial Officer, Principal Accounting Officer

--

Dr. Patrice P. Rioux, M.D., Ph.D.

Acting Chief Medical Officer

--

Mr. Andrew J. Cittadine

Chief Operating Officer

--

会社名

会社名/ポジション

ポジション

株式保有

変動額

Dr. Chandler D. Robinson, M.D.

Chief Executive Officer, Director

73.47K

--

Dr. Christopher M. (Chris) Starr, Ph.D.

Executive Chairman of the Board

16.05K

--

Ms. Lavina Talukdar

Independent Director

14.00K

--

Ms. Kim R. Tsuchimoto

Director

11.49K

--

Mr. Arthur J. Klausner

Independent Director

6.17K

--

Mr. Raymond William (Bill) Anderson

Independent Director

5.37K

--

収益内訳

データなし

データなし

事業別

地域別

データなし

株主

更新時刻: Tue, Aug 19

株主統計

種類

株主統計

比率

Janus Henderson Investors

19.00%

Tactic Pharma LLC

13.33%

Gem Pharmaceuticals LLC

9.90%

Adage Capital Management, L.P.

9.71%

RA Capital Management, LP

8.29%

他の

39.77%

株主統計

比率

Janus Henderson Investors

19.00%

Tactic Pharma LLC

13.33%

Gem Pharmaceuticals LLC

9.90%

Adage Capital Management, L.P.

9.71%

RA Capital Management, LP

8.29%

他の

39.77%

種類

株主統計

比率

Corporation

29.51%

Investment Advisor/Hedge Fund

22.22%

Hedge Fund

15.06%

Venture Capital

8.29%

Investment Advisor

5.82%

Individual Investor

4.75%

Research Firm

0.20%

Pension Fund

0.16%

Bank and Trust

0.07%

他の

13.94%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

76

5.07M

82.91%

-355.61K

2025Q1

72

5.03M

83.96%

+455.96K

2024Q4

54

4.84M

79.28%

+1.76M

2024Q3

40

1.90M

50.69%

+25.14K

2024Q2

43

1.96M

52.51%

+123.52K

2024Q1

46

1.91M

52.92%

+136.66K

2023Q4

44

1.88M

67.20%

+125.61K

2023Q3

42

1.87M

67.45%

+153.91K

2023Q2

38

1.84M

66.75%

+138.58K

2023Q1

38

1.70M

67.19%

-3.29K

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Janus Henderson Investors

1.13M

18.55%

+87.51K

+8.36%

Mar 31, 2025

Tactic Pharma LLC

822.25K

13.45%

-33.33K

-3.90%

Apr 04, 2025

Gem Pharmaceuticals LLC

611.08K

9.99%

--

Apr 04, 2025

Adage Capital Management, L.P.

599.20K

9.8%

--

Mar 31, 2025

RA Capital Management, LP

511.21K

8.36%

--

Mar 31, 2025

AstraZeneca PLC

387.33K

6.33%

+387.33K

--

Oct 23, 2024

Point72 Asset Management, L.P.

168.16K

2.75%

+268.00

+0.16%

Mar 31, 2025

Adar1 Capital Management LLC

100.77K

1.65%

-29.26K

-22.50%

Mar 31, 2025

Geode Capital Management, L.L.C.

48.54K

0.79%

+9.94K

+25.76%

Mar 31, 2025

詳細を見る

66.250USD

Monopar Therapeutics Inc

66.250

概要

企業名

金融

分析